News | June 01, 2021
Jubilant to invest US $92 mn to expand sterile injectable capacity
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
7.94 crore doses were made available to the states in May 2021
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Subscribe To Our Newsletter & Stay Updated
